Xeris Biopharma Holdings

XERS

Market cap $1.52B

Xeris Biopharma (XERS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Please replace the release issued earlier today with the following corrected version that provides additional information regarding the inducement grants. The corrected release reads: XERIS ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4) Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today anno.

CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2026, the Compensation Committee of Xeris' Board of Directors granted restricted stock units for an aggregate of 221,323 shares of its common stock to 47 new employees under Xeris' Inducement Equity Plan. Xeris' Inducement Equity Pla.

CHICAGO--(BUSINESS WIRE)--Xeris Announces Updates to Its Board of Directors.

CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc., a wholly owned subsidiary of Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, announced that today the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance with respect to U.S. Patent Application No. 17/151,405, entitled “Compositions and Methods of Use.” The a.

CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a fast-growing biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that it has entered into separate, privately negotiated exchange agreements with certain holders of its 8.00% Convertible Senior Notes due 2028 (the “Notes”). Pursuant to the exchange agreements, Xeris has agreed, subject to customary closing condit.

Xeris Biopharma has delivered another year of significant revenue growth, signaling a pivotal moment in its trajectory. XERS has reached an inflection point, indicating a shift in its business momentum and future prospects. The article highlights the company's expanding injectable medication portfolio as a driver for recent and anticipated growth.

Xeris Biopharma NASDAQ: XERS reported a sharp increase in first-quarter 2026 revenue and raised the low end of its full-year revenue outlook, citing strong demand for RECORLEV and continued execution across its commercial portfolio.

Xeris Biopharma Holdings, Inc. (XERS) Q1 2026 Earnings Call Transcript

The headline numbers for Xeris Biopharma (XERS) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.